Dasatinib

For research use only.

Catalog No.S1021 Synonyms: BMS-354825

308 publications

Dasatinib Chemical Structure

CAS No. 302962-49-8

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 140 In stock
USD 147 In stock
USD 370 In stock
USD 670 In stock
USD 817 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dasatinib has been cited by 308 publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NUD5[W9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW3NkBp MnnmSG1UVw>? NGHyNXlKSzVyPUCuNFAxODdizszN M1O5XVE4QTV4MEiw
K562 NFrQRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW2dIdlPzJiaB?= M1TtNGROW09? NVrhc4QyUUN3ME2wMlAxOSEQvF2= NF3F[mMyPzl3NkC4NC=>
M07e MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWzO|IhcA>? MlLsSG1UVw>? NHvZWpBKSzVyPUCuNFAyOiEQvF2= NEnUXpMyPzl3NkC4NC=>
ALL3 Mo\sR5l1d3SxeHnjJGF{e2G7 M1zOXVAvOc7:TR?= M3rtUFczKGh? MWPEUXNQ MoDsTWM2OD1yLkCwNFQh|ryP NEW5XYIyQTh6OUW0NC=>
CML M4Psdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmyNEBucW5? MoT6SG1UVw>? MWTJR|UxRTBwMECxJO69VQ>? MUmxPVIyQTBzNh?=
BA/F3 M3;Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPyUm84OiCq NUDL[3ZoTE2VTx?= MXHJR|UxRTZwNUi5JO69VQ>? NVzKO2I{OjNyOEi2OFQ>
BA/F3 NUfSdIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL4O|IhcA>? NXP1OVU6TE2VTx?= MUfJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= NEL2UpAzOzB6OE[0OC=>
BA/F3 NVq0eFNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XNSlczKGh? M1zhOWROW09? MmfXTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>? NIe2cYEzOzB6OE[0OC=>
BA/F3 NWrZU2pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXzO|IhcA>? MYDEUXNQ MYPJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? NH;3OFAzOzB6OE[0OC=>
BA/F3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWC3NkBp MX3EUXNQ M{\1RWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP MVOyN|MxOTdyMx?=
BA/F3 M{PSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4raXFczKGh? NUTw[XYyTE2VTx?= NIrkXZRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= NYDaUnQ{OjN|MEG3NFM>
BA/F3 NWnNV2huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfFO|IhcA>? MVXEUXNQ M2G5Z2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP NV3HeJZOOjN|MEG3NFM>
BA/F3 MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7BeXo4OiCq NFzlNGRFVVOR MnrtTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? NITNcIwzOzNyMUewNy=>
BA/F3 M2Lr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fhVlczKGh? MYDEUXNQ MVPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? M4rzWFI{OzBzN{Cz
BA/F3 NEP1T3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfTPFQ4OiCq MnfMSG1UVw>? MnziTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> NIPyT2UzOzNyMUewNy=>
BA/F3 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nFOlczKGh? M1[3RmROW09? MlzSTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? MU[yN|MxOTdyMx?=
BA/F3 NXTHcXQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLHO|IhcA>? NHzVfmZFVVOR M1f1T2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO M2C3[lI{OzBzN{Cz
BA/F3 NUD5dphjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq0[3A4OiCq MVPEUXNQ NXnGRY5SUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN M2PYTVI{OzBzN{Cz
T cell MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\kU|czKGh? M2\2RmROW09? MX\Jcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> M{X6b|E4OTV2NUGy
WiDr MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDTbG44OiCq M2rlUWROW09? NYfiPJd6UUN3ME2wMlA2OiEQvF2= NYLUdFhuOTV4MUW1NVI>
PC3 NIfx[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDLO|IhcA>? NHXrWpRFVVOR NIrLbm9KSzVyPUCuNFA6PCEQvF2= NW\oTINVOTV4MUW1NVI>
MDA-MB-231 NYDkN4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK3NkBp Mmi0SG1UVw>? NGDLcYlKSzVyPUCuNFEzKM7:TR?= M1LXZ|E2PjF3NUGy
Hs578T M3;rN2N6fG:2b4jpZ{BCe3OjeR?= MmD1O|IhcA>? MmewSG1UVw>? Ml7QS2k2OD1yLkCzJO69VQ>? Ml7qNlQxOTV|Mke=
HMEC MYTDfZRwfG:6aXOgRZN{[Xl? MnzTO|IhcA>? M4\CSWROW09? NHzIdFVIUTVyPUGuPEDPxE1? NIXvRpEzPDBzNUOyOy=>
DU145 MXjDfZRwfG:6aXOgRZN{[Xl? M2PCdVczKGh? NE\qT4lFVVOR NUnTU2ZiT0l3ME2wMlE3KM7:TR?= NFvwcFEzPDBzNUOyOy=>
U251 NEHzSHJEgXSxdH;4bYMhSXO|YYm= M2S1PVczKGh? MYDEUXNQ M3e1WmdKPTB;Mj64NUDPxE1? NHHpXJUzPDBzNUOyOy=>
NCI60 Mny5R5l1d3SxeHnjJGF{e2G7 MnPmO|IhcA>? MkXPSG1UVw>? NUfkR3I3T0l3ME21Mlch|ryP M1fQflI1ODF3M{K3
MALME-3M NWOxbI1bS3m2b4TvfIlkKEG|c3H5 MXe3NkBp NEHWXGxFVVOR M2X6OWdKPTB;Nj62NUDPxE1? M{DMT|I1ODF3M{K3
KM12 M3K1TWN6fG:2b4jpZ{BCe3OjeR?= M4TCVFczKGh? MYXEUXNQ NXzhbFFST0l3ME23MlQ1KM7:TR?= NGf2T2IzPDBzNUOyOy=>
SW620 MYrDfZRwfG:6aXOgRZN{[Xl? NHPXfJc4OiCq MoLvSG1UVw>? NVvFOJJ{T0l3ME24MlQ{KM7:TR?= NFO3ToMzPDBzNUOyOy=>
RXF 393NL M4H2NGN6fG:2b4jpZ{BCe3OjeR?= NI\qeXA1KGSjeYO= NIjpO4JFVVOR MVTJR|UxRTBwMEKxO{DPxE1? NUnN[VJMOjN{NUOwO|Q>
LXFA 983L MUDDfZRwfG:6aXOgRZN{[Xl? NHy1U3Q1KGSjeYO= M2f5ZmROW09? MlPnTWM2OD1yLkC1OlUh|ryP MUWyN|I2OzB5NB?=
PRXF DU145 MYjDfZRwfG:6aXOgRZN{[Xl? M4XHWlQh\GG7cx?= NUfoUJRZTE2VTx?= NIqzRoJKSzVyPUCuNFYzOyEQvF2= NV\yXYdxOjN{NUOwO|Q>
PAXF 1657L NH\HUnBEgXSxdH;4bYMhSXO|YYm= M1y0VlQh\GG7cx?= NG\QSo1FVVOR M4rtXmlEPTB;MD6xNlEh|ryP NIr6[4wzOzJ3M{C3OC=>
CXF 1103L NIXTe3hEgXSxdH;4bYMhSXO|YYm= M{jPfVQh\GG7cx?= NH\pNlBFVVOR M1XTdGlEPTB;ND6zOkDPxE1? MX2yN|I2OzB5NB?=
GXF251L MVvDfZRwfG:6aXOgRZN{[Xl? MVe0JIRigXN? M13sNGROW09? Mn;YTWM2OD1{LkK1JO69VQ>? M{DBNFI{OjV|MEe0
NCI-H23 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7IeHc4OiCq NFn0VGdFVVOR MoPLTWM2OD1{LkK3JO69VQ>? MkPCNlM2OjFyMkC=
HCT116 M4W5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3NkBp Mn3tSG1UVw>? M13wZWlEPTB;Mj6zJO69VQ>? MWqyN|UzOTB{MB?=
MCF7 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPkU4NpPzJiaB?= MlPySG1UVw>? M4TqPWlEPTB;Mj61O{DPxE1? MXSyN|UzOTB{MB?=
NCI-H460 NY[wZYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzyO|IhcA>? MV7EUXNQ NF;CclBKSzVyPUiuPVkh|ryP NXXQeIJCOjN3MkGwNlA>
DLD1 NESzXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW3VYw4OiCq NIfUPXFFVVOR NYPNWW9tUUN3ME20MlYh|ryP M2T5bFI{PTZ5OU[w
NCI-H661 NUnR[2RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPpfGJDPzJiaB?= NXjZcZJQTE2VTx?= NIj4U2hKSzVyPUeuPEDPxE1? NFH6cFYzOzV4N{m2NC=>
A549 NEDKZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzaSoR[PzJiaB?= NUHRTXZWTE2VTx?= MnjGTWM2OD16LkKg{txO M1TMO|I{PTZ5OU[w
U937 NFzubWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLMUohPPzJiaB?= NY\jcYY2TE2VTx?= M1freWlEPTB;MUKuNkDPxE1? M1TYXVI{PTZ5OU[w
HEK293 Ml7KSpVv[3Srb36gRZN{[Xl? MmT1NVDDqM7:TR?= MX\EUXNQ MVzJcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= Mne0NlI4PzB4MUC=
HUVEC MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjjRYIxNjF3wrFOwG0> NU[0cGFkPzJiaB?= MUDEUXNQ NGqxSoFKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> MmXXNlI5PTN7OUO=
HUVEC MX3GeY5kfGmxbjDBd5NigQ>? M1zoVFE2yqEQvF2= MVe3NkBp MlTRSG1UVw>? NXy4SFhuUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? NF;rW4YzOjh3M{m5Ny=>
Plasmodium falciparum NEHFVWJHfW6ldHnvckBCe3OjeR?= NFLi[VMyOMLizszN NF\jeVYyPSCvaX6= MkTLSG1UVw>? NF\aTHZKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? MlnRNlQ2PTB|M{C=
PC3 MmDRSpVv[3Srb36gRZN{[Xl? MYWwMlEh|ryP M2DCdVUhcA>? MYTEUXNQ NHTFblhKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NUHaVXVsOTl2NkK5O|U>
DU145 M3TzcmZ2dmO2aX;uJGF{e2G7 M{TxTFAvOSEQvF2= Mm\uOUBp M33sXmROW09? MUjJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MoTSNVk1PjJ7N{W=
PC3 M3PhUmtqdmG|ZTDBd5NigQ>? NYX0SXV6OC5zIN88US=> M3;vZ|UhcA>? MX\EUXNQ NVzVSm46UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> M2\ybFE6PDZ{OUe1
DU145 NHXLdmNMcW6jc3WgRZN{[Xl? MW[wMlEh|ryP MWe1JIg> MWHEUXNQ NUeydHJHUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O M3;BSFE6PDZ{OUe1
PC3 MUHLbY5ie2ViQYPzZZk> NGnQbmQxNjFizszN MUe1JIg> MVnEUXNQ M1rnRWlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NUDjNFh1OTl2NkK5O|U>
DU145 MYrLbY5ie2ViQYPzZZk> NUj3S|JGOC5zIN88US=> M1HlPFUhcA>? MULEUXNQ MYHJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>? NEfxR5UyQTR4Mkm3OS=>
Huh7 NGi4T|hCdnSrdnnyZYwhSXO|YYm= NF7aO5EzNjVizszN M{fISVQh\GG7cx?= NYniXIJITE2VTx?= M2jje2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= MYSxO|M3ODZ5Nh?=
C6/36 M3nubmFvfGm4aYLhcEBCe3OjeR?= NF34cHgzNjVizszN M2q0XlQh\GG7cx?= NVnOUWtFTE2VTx?= MVzJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO MoLWNVc{PjB4N{[=
U937 NHr4RVVHfW6ldHnvckBCe3OjeR?= MV6xJO69VQ>? MnzFNUBp MXHEUXNQ MX;S[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MlG4NVc3QDRyOUm=
U937 M1PUd2Z2dmO2aX;uJGF{e2G7 M3HNd|Eh|ryP MUOxJIg> MVXEUXNQ Mln0VoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> NYPyUWQ2OTd4OESwPVk>
murine mast cell NIDrSWNHfW6ldHnvckBCe3OjeR?= MlrnNUDPxE1? NVfmXmE1OjRiaB?= M4XCPGROW09? Mkj6TY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1? NEDnOXgyPzZ6NEC5PS=>
BV-173 M4D5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G1fGlEPTB;MD6wNFAxODBzMEmg{txO MV\TRW5ITVJ?
K-562 NH;Zc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX6UpZKSzVyPUCuNFAxODByMk[2JO69VQ>? MoryV2FPT0WU
BL-70 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom1TWM2OD1yLkCwNFAxODh{MjFOwG0> MXfTRW5ITVJ?
EM-2 M4H0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7kT2lOUUN3ME2wMlAxODByMUC4JO69VQ>? MYrTRW5ITVJ?
LAMA-84 M1;NOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrCSmlKSzVyPUCuNFAxODB|MkGg{txO M{Dn[3NCVkeHUh?=
MEG-01 NUjIOJNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMECwNFA6QCEQvF2= MkjsV2FPT0WU
EoL-1-cell NV3YXmtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfkTWM2OD1yLkCwNFAyOzFizszN M13l[3NCVkeHUh?=
CTV-1 M4nj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOyPFZKSzVyPUCuNFAxODRyNDFOwG0> MkL2V2FPT0WU
TE-15 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTSUWdKSzVyPUCuNFA2QDlizszN NVTEO5lsW0GQR1XS
NOS-1 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzQb4dMUUN3ME2wMlAxPjF|IN88US=> MmfLV2FPT0WU
D-336MG NFnsTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEC2N{DPxE1? NVvjdIZUW0GQR1XS
LB1047-RCC M1nlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHIS|VZUUN3ME2wMlAxQTh7IN88US=> MofoV2FPT0WU
LB996-RCC NIXE[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z5c2lEPTB;MD6wNFk6OSEQvF2= MmjTV2FPT0WU
SW982 NXrVdItQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DDOGlEPTB;MD6wNVEyPSEQvF2= NFixeo9USU6JRWK=
TK10 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG1SlExUUN3ME2wMlAyOTd2IN88US=> MmDBV2FPT0WU
A704 NXiwZlFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnnU2k2UUN3ME2wMlAyPDlzIN88US=> M4P3VHNCVkeHUh?=
TE-8 M{Gydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HkWGlEPTB;MD6wNVU4PiEQvF2= MV3TRW5ITVJ?
DOHH-2 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXiTWM2OD1yLkCxO|E6KM7:TR?= MmrGV2FPT0WU
HOP-62 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPTTWM2OD1yLkCxPFM1KM7:TR?= M2HXcHNCVkeHUh?=
TE-12 M{LO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;6NHFKSzVyPUCuNFE5PjFizszN MlHPV2FPT0WU
KGN NWDxdG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEG5OFIh|ryP NYnr[3A{W0GQR1XS
NCI-H1648 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLTTWM2OD1yLkCyNFEyKM7:TR?= M4fYcXNCVkeHUh?=
OS-RC-2 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[5ZlRKSzVyPUCuNFIxOyEQvF2= MW\TRW5ITVJ?
GB-1 M4e3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEKxOVch|ryP MoDDV2FPT0WU
RXF393 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfrTWM2OD1yLkCyN|U4KM7:TR?= MnH3V2FPT0WU
LC-2-ad MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPxTI9KSzVyPUCuNFI2QDZizszN MXvTRW5ITVJ?
KS-1 M133fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXjd2FsUUN3ME2wMlAzPzNizszN MUDTRW5ITVJ?
ETK-1 NVXtOYZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj0TWM2OD1yLkCyPFMzKM7:TR?= M4TiO3NCVkeHUh?=
SW954 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC5TWM2OD1yLkCyPVI4KM7:TR?= NYfLdmN5W0GQR1XS
Becker M3HHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfzTZJKSzVyPUCuNFMxODNizszN NV;kTnZUW0GQR1XS
MZ1-PC NIjrWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7icHFKSzVyPUCuNFMyOTlizszN NHfI[IFUSU6JRWK=
ES6 NV7VTGRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[5[pNHUUN3ME2wMlA{OTl|IN88US=> M{XYSXNCVkeHUh?=
KURAMOCHI NH;QVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvCVVlvUUN3ME2wMlA{PDh5IN88US=> NVXrWZJSW0GQR1XS
CGTH-W-1 NFr2c3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3OmdKSzVyPUCuNFM2PDhizszN Mo[1V2FPT0WU
VA-ES-BJ MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPCR2FKSzVyPUCuNFM6ODJizszN NWf5W3E2W0GQR1XS
LXF-289 NHnMR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEO5OVYh|ryP MmnoV2FPT0WU
MPP-89 M{POZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjhTWM2OD1yLkC0NFQ6KM7:TR?= MVXTRW5ITVJ?
SW872 M4LqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\DSlBKSzVyPUCuNFQyPjFizszN MkfWV2FPT0WU
SNB75 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq1TWM2OD1yLkC0OFM2KM7:TR?= M{mzRnNCVkeHUh?=
PSN1 MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf4ZZoyUUN3ME2wMlA1PDd2IN88US=> NHX5TG1USU6JRWK=
LB831-BLC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnsVohUUUN3ME2wMlA1PjB7IN88US=> M4K5WHNCVkeHUh?=
MFH-ino MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQWWlEPTB;MD6wOFczPCEQvF2= NYSzPFZbW0GQR1XS
TGBC24TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn4NHJGUUN3ME2wMlA1PzZzIN88US=> Mnf2V2FPT0WU
A388 NWnaUZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEWwPVUh|ryP M3LPZnNCVkeHUh?=
BB30-HNC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\wVFlKSzVyPUCuNFU1OzdizszN Ml\lV2FPT0WU
GI-ME-N MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHpOnhKSzVyPUCuNFYyOThizszN MYDTRW5ITVJ?
TGBC1TKB M1v6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvvbJdKSzVyPUCuNFYyPjRizszN NIPtO5VUSU6JRWK=
TE-10 NGnreXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PreWlEPTB;MD6wOlM2PyEQvF2= MWPTRW5ITVJ?
A498 NXLLToNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEeyPFQh|ryP MY\TRW5ITVJ?
TE-11 M{jRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfMeGRKSzVyPUCuNFc5PThizszN NGD6WZdUSU6JRWK=
BB65-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TyTmlEPTB;MD6wPFIzPyEQvF2= MoHpV2FPT0WU
C2BBe1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjNS4xHUUN3ME2wMlA5OzB6IN88US=> NGXCe2hUSU6JRWK=
NCI-H747 NVLDPIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMEizOlIh|ryP M3TZO3NCVkeHUh?=
IST-MES1 M3nGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HX[WlEPTB;MD6wPFU2OiEQvF2= M1jQSnNCVkeHUh?=
KALS-1 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XDOWlEPTB;MD6wPVQ6KM7:TR?= M{fvSnNCVkeHUh?=
GCIY NET3bpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXvTnNKSzVyPUCuNFk3PTZizszN NWLt[pJYW0GQR1XS
RL95-2 NYXFfY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3JT4lKSzVyPUCuNVA{QCEQvF2= M3TtXHNCVkeHUh?=
TE-1 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrLbmZjUUN3ME2wMlExPTRizszN NITnXYhUSU6JRWK=
NCI-H1355 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jzcGlEPTB;MD6xNVAzQCEQvF2= NVnuc4JQW0GQR1XS
SW962 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkexTWM2OD1yLkGxNlkzKM7:TR?= MXvTRW5ITVJ?
KLE MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe0R21{UUN3ME2wMlEyOzF5IN88US=> NI\KSHVUSU6JRWK=
MC116 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPFdXlKSzVyPUCuNVE1OSEQvF2= M4DFUXNCVkeHUh?=
NMC-G1 M1q2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Pcm9KSzVyPUCuNVE3ODZizszN NHn1V5VUSU6JRWK=
KU812 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe0TWM2OD1yLkGxPFg{KM7:TR?= M2fwUnNCVkeHUh?=
COLO-829 NUnUO2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMUKyNVMh|ryP MUHTRW5ITVJ?
NTERA-S-cl-D1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XqbmlEPTB;MD6xNlI5OyEQvF2= MUPTRW5ITVJ?
IST-MEL1 NFztR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDZTWM2OD1yLkGzOFUh|ryP M{LuNXNCVkeHUh?=
MLMA MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMUSwN|Ih|ryP M{XKNXNCVkeHUh?=
LS-123 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LLT2lEPTB;MD6xOFA3PCEQvF2= MnLZV2FPT0WU
LB2518-MEL NWD0d2hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DJW2lEPTB;MD6xOFE3OiEQvF2= NWjOVohxW0GQR1XS
NB69 NELaTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj5TWM2OD1yLkG0OFM3KM7:TR?= MmmzV2FPT0WU
8-MG-BA Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe3ZohmUUN3ME2wMlE2PDV6IN88US=> MnXwV2FPT0WU
K5 NFG5b2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PRPGlEPTB;MD6xOlQ5QSEQvF2= M4rnPXNCVkeHUh?=
KINGS-1 NXy3W2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXoN4p7UUN3ME2wMlE3PjZ4IN88US=> M1XHN3NCVkeHUh?=
SF268 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMUe0NFQh|ryP MYrTRW5ITVJ?
PF-382 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMUe2O|gh|ryP NHPMV5RUSU6JRWK=
SH-4 NGS0OmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMUi0NVMh|ryP M3;GbXNCVkeHUh?=
NALM-6 MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\jWmlEPTB;MD6xPVI6PSEQvF2= M2XCWnNCVkeHUh?=
CP66-MEL M4i3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXNSFZKSzVyPUCuNVk2OzFizszN M1;acnNCVkeHUh?=
697 NU\sVmM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH1TWM2OD1yLkG5PVg4KM7:TR?= MVjTRW5ITVJ?
CP67-MEL MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDqT5pKSzVyPUCuNlA1QDhizszN NYDo[FZkW0GQR1XS
DSH1 Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP2[21KSzVyPUCuNlQxODFizszN M4S3SnNCVkeHUh?=
HCE-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMk[0N|kh|ryP M1T1N3NCVkeHUh?=
MZ2-MEL MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHnTWM2OD1yLkK4OVM4KM7:TR?= NVXMZmlYW0GQR1XS
BL-41 M2P4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PSd2lEPTB;MD6yPVEzOyEQvF2= MnXtV2FPT0WU
HUTU-80 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwM{G0NkDPxE1? M2rHWHNCVkeHUh?=
LOXIMVI NV;xPVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwM{G1NFMh|ryP M3TlcnNCVkeHUh?=
no-10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTvOIZKSzVyPUCuN|E6OzFizszN MlTJV2FPT0WU
KARPAS-422 NVfLUJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zMXmlEPTB;MD6zN|k6PyEQvF2= MVHTRW5ITVJ?
SW684 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwM{S5PEDPxE1? NGrwfHpUSU6JRWK=
SF126 M{XWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPxTWM2OD1yLkO1OFEh|ryP MoDQV2FPT0WU
D-263MG M{fMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7LZZBbUUN3ME2wMlM3OjJ2IN88US=> MlHGV2FPT0WU
OVCAR-4 NF7xe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\MWZRKSzVyPUCuN|c1OzNizszN NUfaTZZQW0GQR1XS
BB49-HNC NVLXRoJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;jTWM2OD1yLkO4OVk6KM7:TR?= M3OxS3NCVkeHUh?=
ONS-76 NXzQ[Ys{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\NSnQ5UUN3ME2wMlQzQTVzIN88US=> M17XUHNCVkeHUh?=
MZ7-mel M3\1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjIeIlKSzVyPUCuOFc6OTFizszN NYe2cmZjW0GQR1XS
RCC10RGB NGT5U3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwNEmxNUDPxE1? NXrSWGluW0GQR1XS
BOKU NInLSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwNEmxN|Mh|ryP MnrCV2FPT0WU
no-11 M{P5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;XfY5KSzVyPUCuOVAzOjhizszN M13tb3NCVkeHUh?=
IST-SL2 NEmz[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\HTohYUUN3ME2wMlUxOzB{IN88US=> MUPTRW5ITVJ?
RKO NWj4fJlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTZTWM2OD1yLkWyPVY3KM7:TR?= NEnvNGVUSU6JRWK=
HT-144 NGfiTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrvepNKSzVyPUCuOVM3ODlizszN NEXyfG1USU6JRWK=
NCI-H446 NIm5OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwNkK3OkDPxE1? MYTTRW5ITVJ?
QIMR-WIL MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS2clI2UUN3ME2wMlcxPjJ7IN88US=> MoPMV2FPT0WU
MHH-PREB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwN{S0Olkh|ryP M1\BV3NCVkeHUh?=
EW-16 M1zKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXCTWM2OD1yLke2NVc5KM7:TR?= MYjTRW5ITVJ?
EW-24 NWHvbnNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwN{ixOlUh|ryP MVPTRW5ITVJ?
LB373-MEL-D M3f1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjWU4dKSzVyPUCuPFI2ODhizszN NVHXSmxjW0GQR1XS
TE-9 M{XGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq3PZBKSzVyPUCuPFc2OzJizszN MXrTRW5ITVJ?
A3-KAW NXvQW4RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C5PGlEPTB;MD65PFQ2OiEQvF2= NVi0UHNVW0GQR1XS
A101D NHSwXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwMEOwOFMh|ryP M3L6NHNCVkeHUh?=
OCUB-M NHPsN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFwMES0NVIh|ryP M4jGdHNCVkeHUh?=
ES4 M3ezWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPSTWM2OD1zLkC1NVQ2KM7:TR?= NYHjNoJCW0GQR1XS
TE-6 NGjOe|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFRmdKSzVyPUGuNlEzOjZizszN NXzTS2VyW0GQR1XS
D-502MG NXXsOmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y1TGlEPTB;MT6yN|M4PiEQvF2= Mo\qV2FPT0WU
KNS-42 M1:3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj0TWM2OD1zLkK0OFEzKM7:TR?= MVnTRW5ITVJ?
SNU-C2B MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLEUlVKSzVyPUGuN|A2QDlizszN NUHEOZpvW0GQR1XS
NCI-H1838 NHLIdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fWOmlEPTB;MT6zNFc{OyEQvF2= M1nvUXNCVkeHUh?=
NKM-1 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\JTWM2OD1zLkOwPFU6KM7:TR?= NVjLPVRHW0GQR1XS
GI-1 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfkTWM2OD1zLkO2NlIh|ryP NUG5fY94W0GQR1XS
NB5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDGR2V4UUN3ME2xMlM6QDJ5IN88US=> NHfoUGtUSU6JRWK=
CAS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvHe2ZKSzVyPUGuOFA6QTJizszN MYPTRW5ITVJ?
HCE-T MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwNU[3NVQh|ryP MVnTRW5ITVJ?
SBC-1 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPsTWM2OD1zLkW3PVg1KM7:TR?= NWW2U2dVW0GQR1XS
JiyoyeP-2003 NGnUNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTFwN{O0OlYh|ryP M3S1UHNCVkeHUh?=
TE-5 NYPRRXp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnhdGRSUUN3ME2xMlc6OTN7IN88US=> MnzPV2FPT0WU
CAN M1rkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf2TWM2OD1zLkiyNlUzKM7:TR?= NH\tcndUSU6JRWK=
SK-UT-1 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjWPZFIUUN3ME2yMlE3Pjl|IN88US=> MYHTRW5ITVJ?
JVM-2 NWCybnhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[yPJk{UUN3ME2yMlM3Ojh2IN88US=> MXjTRW5ITVJ?
LB771-HNC NV3Pe21rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[yUYVKSzVyPUKuOVc2PTFizszN NHHMfnlUSU6JRWK=
NCCIT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP6eIRKSzVyPUKuPFY3OTZizszN MnPhV2FPT0WU
NCI-H2126 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPTcW9KSzVyPUKuPFc2PTJizszN MkXlV2FPT0WU
Calu-6 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD1|LkC1O|QyKM7:TR?= NWPIcHZFW0GQR1XS
SK-LMS-1 NWXoeWF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vwOmlEPTB;Mz6xNVg5PiEQvF2= M1;RdnNCVkeHUh?=
ARH-77 NIHufYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwNE[5NVUh|ryP MVfTRW5ITVJ?
NB17 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD3XoF[UUN3ME2zMlY{QDR5IN88US=> MWLTRW5ITVJ?
A253 NEHGbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwN{OyOFYh|ryP MkDMV2FPT0WU
OPM-2 NHXOfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTRwMke2PFUh|ryP M3fMVnNCVkeHUh?=
MV-4-11 NFzNN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljHTWM2OD12LkO2OFU1KM7:TR?= MX\TRW5ITVJ?
SR MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRwNEm5OVQh|ryP MnTYV2FPT0WU
KG-1 NHWyOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXvbWlKSzVyPUSuOlA5PDVizszN MV;TRW5ITVJ?
OCI-AML2 M3[xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\nfIFKSzVyPUWuPFYyPTRizszN NVux[oNOW0GQR1XS
D-247MG MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4frWmlEPTB;Nj6xNlUyQSEQvF2= NWPQWWtPW0GQR1XS
DJM-1 NFXrd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DmOGlEPTB;Nj60PFU2QCEQvF2= MlXvV2FPT0WU
RPMI-6666 M4[0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmThTWM2OD15LkK3NFY4KM7:TR?= MV3TRW5ITVJ?
KARPAS-45 NVLW[JJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TSVWlEPTB;Nz61NVY4OSEQvF2= M1vDdnNCVkeHUh?=
LP-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ywbWlEPTB;Nz61OFc5OiEQvF2= M3XUe3NCVkeHUh?=
RS4-11 M130XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXYTWM2OD15Lk[1O|g4KM7:TR?= M1T0SHNCVkeHUh?=
DU-4475 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPGTWM2OD16LkKxOlUzKM7:TR?= MnXsV2FPT0WU
MONO-MAC-6 M3\1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHPfopQUUN3ME24MlI4ODZ4IN88US=> NGi3eHpUSU6JRWK=
NCI-SNU-16 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKyUWFKSzVyPUiuOVYyOjhizszN NGTuNHNUSU6JRWK=
SJSA-1 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7WcVFUUUN3ME24MlczQDB3IN88US=> NYH6UW8{W0GQR1XS
MMAC-SF MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWntNXJkUUN3ME24Mlc6OzB5IN88US=> MlvhV2FPT0WU
SK-NEP-1 M4HKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu2TnJKSzVyPUiuPFkyPTVizszN NFfUPXdUSU6JRWK=
J-RT3-T3-5 M2rHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DmZmlEPTB;OD65OlUzQSEQvF2= MUHTRW5ITVJ?
SKM-1 M335Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHZTWM2OD17LkCxO|M1KM7:TR?= M3;ROnNCVkeHUh?=
LB2241-RCC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH1THdIUUN3ME25MlAzODF{IN88US=> NIn1To1USU6JRWK=
SIG-M5 M{DDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm4N|lKSzVyPUmuNFI1QTNizszN M2i5cHNCVkeHUh?=
EVSA-T NHLIRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fBeGlEPTB;OT6yO|c6OyEQvF2= MVPTRW5ITVJ?
GT3TKB MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrze2FqUUN3ME25MlM2PTR4IN88US=> M17DcnNCVkeHUh?=
NB6 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jZVmlEPTB;OT65NlI2QSEQvF2= NH\FfYpUSU6JRWK=
EHEB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDVTmhlUUN3ME2xNE4xPjV4IN88US=> MnHUV2FPT0WU
HEL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXIOVlKSzVyPUGwMlQ4PzZizszN M4TmPXNCVkeHUh?=
ALL-PO NVrFTYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfjPXBJUUN3ME2xNE44QTN6IN88US=> NHP1WZJUSU6JRWK=
TGW NFPCUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3TWM2OD1zMT6yPFI5KM7:TR?= MXTTRW5ITVJ?
BC-3 NIK4fohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF{LkGxN|gh|ryP M4DkT3NCVkeHUh?=
IA-LM NYHReIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF{LkS0OFUh|ryP M2js[nNCVkeHUh?=
UACC-257 M1jabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF{LkmxPVgh|ryP NUHZO2J{W0GQR1XS
KP-N-YS NGjsVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWwTWM2OD1zMj65Nlg{KM7:TR?= NGXKeIpUSU6JRWK=
Raji MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF|Lke0PVch|ryP MWDTRW5ITVJ?
SF539 NELZd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DFNWlEPTB;MUOuPFU2PyEQvF2= MWPTRW5ITVJ?
DMS-153 M{HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H2UGlEPTB;MUSuNFAzQCEQvF2= MkHJV2FPT0WU
L-540 NI\tWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H3UWlEPTB;MUWuNFY4OiEQvF2= NFu2cnZUSU6JRWK=
MN-60 M4LXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDMclhKSzVyPUG1MlE6PzlizszN M1e0XnNCVkeHUh?=
RPMI-8866 NYi5[3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i0b2lEPTB;MUeuOFQ2PCEQvF2= NFTN[mJUSU6JRWK=
NCI-H510A MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF7LkO5O|Mh|ryP MmTrV2FPT0WU
NB13 M3:zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnzOGRKSzVyPUG5MlQ5PzdizszN NGWwcpFUSU6JRWK=
HAL-01 MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrmUXcyUUN3ME2xPU44PTR|IN88US=> M4X3c3NCVkeHUh?=
NCI-H720 Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLyTWM2OD1{MD6yO|M{KM7:TR?= MlPrV2FPT0WU
REH NUXlNWs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C4TWlEPTB;MkCuOlM2PyEQvF2= MknpV2FPT0WU
KNS-81-FD M{fRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom4TWM2OD1{Mz6xOFYh|ryP MlX6V2FPT0WU
HC-1 NWWw[FdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v3d2lEPTB;MkSuOVU2OSEQvF2= NXzMd2lLW0GQR1XS
NCI-H2141 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWexeFVMUUN3ME2yOE44PzV2IN88US=> MYHTRW5ITVJ?
MOLT-4 M1nEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1roTWlEPTB;Mk[uOlc2OyEQvF2= NGHyOlhUSU6JRWK=
OMC-1 M{HFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvvVFNKSzVyPUK3MlE1OjJizszN NYX3TXZjW0GQR1XS
LC-1F MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7uTWM2OD1{Nz6zNlQ2KM7:TR?= MkLBV2FPT0WU
NCI-H1304 M1O5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPCcmZKSzVyPUK4MlE3OjhizszN NUK4dIFXW0GQR1XS
BC-1 NWq3XJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ6Lk[1NUDPxE1? MX\TRW5ITVJ?
NCI-H64 NVyzN|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDFOlJKSzVyPUK5MlYzPTNizszN M2XG[HNCVkeHUh?=
MOLT-16 NHjUT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ7Lk[yPVIh|ryP NULTbGxYW0GQR1XS
U-87-MG MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvvTWM2OD1|MD63OlYh|ryP NYXMSVc2W0GQR1XS
GAK NEixSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqySoVvUUN3ME2zNU4zPjh4IN88US=> MnXIV2FPT0WU
ES8 NGXwW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\1RVB[UUN3ME2zNk4yOjV{IN88US=> MWTTRW5ITVJ?
HCC1599 NETQTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN{LkOzNlUh|ryP NIG5[INUSU6JRWK=
EB-3 NUXXfpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDYU3ZKSzVyPUO0MlMyOTdizszN MVXTRW5ITVJ?
HCC1187 MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjSZZVlUUN3ME2zOU45ODV{IN88US=> MkLNV2FPT0WU
SK-PN-DW MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfzS21KSzVyPUO2MlE6PDNizszN M1HudHNCVkeHUh?=
JVM-3 NXfoZnd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUntVndmUUN3ME2zO{4zOzN6IN88US=> MnvXV2FPT0WU
HCC2157 NGDm[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\2VmlEPTB;M{euPVk1PiEQvF2= NXvNRZRzW0GQR1XS
A4-Fuk NYr4VFM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\Mb5ZKSzVyPUO4MlExODlizszN M1KwcHNCVkeHUh?=
COR-L279 NWLNVlZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjwRZVKSzVyPUSwMlI5PTFizszN M1nBcHNCVkeHUh?=
DEL MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTRzLkmwPFYh|ryP NIj2R49USU6JRWK=
NCI-H1395 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjFUXNHUUN3ME20Nk4xOTZ|IN88US=> MlzRV2FPT0WU
MHH-NB-11 NETFe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nXfGlEPTB;NEOuNFgyQCEQvF2= MWPTRW5ITVJ?
NCI-H2107 NX\zW3Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;kPFBKSzVyPUSzMlQ5PDZizszN M1z0UnNCVkeHUh?=
NEC8 M{LxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DxeGlEPTB;NESuN|M3KM7:TR?= MXXTRW5ITVJ?
COLO-684 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW3TWM2OD12Nj6yNlU5KM7:TR?= Moq3V2FPT0WU
LS-411N MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLZ[mVnUUN3ME20PE41PzR6IN88US=> NX;xWYxnW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

- Collapse
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825
Smiles CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Recruiting Drug: Dasatinib + Quercetin Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic February 14 2020 Phase 1|Phase 2
NCT04155411 Recruiting Drug: Dasatinib Dasatinib|BCR-ABL|Chronic Myeloid Leukemia Shenzhen Second People''s Hospital December 1 2019 Phase 4
NCT04115059 Recruiting Drug: Dasatinib Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 4 2019 Phase 1
NCT03318770 Not yet recruiting Drug: Dasatinib and blinatumomab Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Drug: Dasatinib Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID